Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? - Wikidata - wikimedia - TriplyDB

Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

http://www.wikidata.org/entity/Q38196931

about

Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?T-cell Lymphoma Epidemiology: the Known and Unknown.Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Rapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapy Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.Doxycycline is an NF-κB inhibitor that induces apoptotic cell death in malignant T-cells.Management Strategies for Mycosis Fungoides in India.Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.Sézary Syndrome: Clinical and Biological Aspects.The biomarker landscape in mycosis fungoides and Sézary syndrome.Gelling Your Dermatology Nursing Practice: A Practical Guide for Managing the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel.Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices.Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.Prognostic indicators for mycosis fungoides in a Greek population.Altered microRNA expression in folliculotropic and transformed mycosis fungoides.Eosinophils in the skin-a red herring masking lymphoma: a case series.Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides

P2860

Q30239965-6D6E20AD-DD91-4A45-9681-56E6CFF4B1D5 Q30239985-B7224A92-6F6F-4280-8855-D8A374E0C6FA Q30252152-CE16D800-17DB-44F7-98C6-AB438FCA9C19 Q30276132-43BC4DC0-084C-4F89-9C76-1F491DC33ABD Q34489388-A9DC7FEC-F212-4BAB-9FBE-82B79DFFCF38 Q35669880-824CFB21-9736-4E6E-B147-1AED1229CA28 Q35825986-79C4AB5D-2620-4368-898C-53E7B4801846 Q36793430-7A06E1BF-0635-4A74-8ED9-F303B82D9B51 Q37163606-D049A949-38E5-4C26-996B-D06344BEF726 Q37689051-18B9EEB1-68C7-479E-B75C-0E721EC92204 Q37717711-A6A92123-D354-4F8F-8E49-EEEBFDC56A07 Q37723390-3246C4AD-365D-444F-9A32-CA626CA65FE1 Q38765889-D6EDDD4E-22D7-4F84-99B5-0B58ED4E0D78 Q38814744-03C6641F-F3C6-43E0-893A-2FAE57285F88 Q39023382-B08C27A4-517F-42BA-B8DA-AE0D3E04C730 Q39321371-1FFC250E-B054-49EE-81E8-D12B4C4876BA Q39432325-A7A90BD8-2DD1-4528-B2CB-A010A3D83AFA Q40790489-6FCA6813-500B-4258-A868-7B299648B644 Q47898250-0F44E15C-5D5B-46A1-AC0F-E220E2326723 Q48296904-54203BF1-AC7D-4549-98A7-157C1ABCA40B Q48650197-60D23146-3824-486D-8B78-91F3146786F1 Q52857590-84ED8632-6D33-45B8-ADB7-2356B4CEF9ED Q53039521-8C2C00CF-8FA5-4301-9BA4-1F8F07A6C0F2 Q53223479-3C6BCD29-716E-4DCD-85BF-8FD72F673C5D Q55434286-621D9A82-B913-460A-8271-E1CB81C92505 Q58777674-9AEE8A92-11B7-4E8C-9521-CCA50F1B86B1

P2860

Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?

http://www.wikidata.org/entity/Q38196931

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Prognostic factors, prognostic ...... ry syndrome: where are we now?

@en

type

label

Prognostic factors, prognostic ...... ry syndrome: where are we now?

@en

prefLabel

Prognostic factors, prognostic ...... ry syndrome: where are we now?

@en

P1433

Q38196931-3FADF2C1-BFEA-4120-90FD-9163086D276F

P1476

Q38196931-5CD0C5DB-7853-4F0D-89FB-2A2455D6F58F

P2093

Q38196931-328742C3-D8FA-4448-8BCE-81FE2E17C1BA

Q38196931-5821EF1E-0F71-4CDF-91A5-4D3A5EBE4BD6

Q38196931-7EA19A27-1686-4D95-8AC3-688B0815726C

Q38196931-9C97C651-7D73-4280-89FB-FE0351EFDF2E

Q38196931-A3C30FDE-A6AD-408B-8B84-8F262066A13A

Q38196931-BCCA2A0D-64C5-4336-A93D-447C3D2C9DA5

Q38196931-FDD1450D-CD25-4E79-B07E-87809A5EBEF4

P2860

Q38196931-04FA13CB-8263-4EC6-A9F6-B0DF5EF3EC47

Q38196931-08903217-572C-495C-BAC8-1E8CACF273EF

Q38196931-0BFA3A71-E0B3-482C-8300-930847B5E918

Q38196931-0D0C45D9-6068-4CCC-8EAF-972BF5126138

Q38196931-1325C78F-DFAC-4B16-8184-90DDD9B70741

Q38196931-18726C02-25A4-4CE1-96C6-3CB438340158

Q38196931-1A196B6A-2CF6-4C14-B38A-90DA99982ADB

Q38196931-1DC97040-703D-4976-8175-9E28E9844171

Q38196931-1DDE20EB-D88A-43E6-AC82-653CCEBEBC29

Q38196931-234E7C45-3556-478C-BE71-4C9659B4D7E9

P304

Q38196931-6F70F488-5012-4F75-8A04-1A2596BB2E77

P31

Q38196931-B69679E3-C1EC-4E8E-A5B8-9EE0F814AE19

P356

Q38196931-C8C6229C-3D63-4A14-81C3-FB1DAE3A8627

P407

Q38196931-ED3BBA03-69A5-465C-BACB-9A4F934D57F7

P433

Q38196931-ACE4DD86-6027-45D9-9389-EEC418D3458E

P478

Q38196931-D5D6A366-D761-418B-BCCB-497D14A4BD2E

P577

Q38196931-92D9E13D-261D-4AEF-85E5-61A9BAC27163

P5875

Q38196931-0A04D70C-1E7C-4177-B1CC-4696AA8A9231

P698

Q38196931-F6C4B6AE-95A0-467C-84D2-7E8DC43B6D2E

P356

P1433

British Journal of Dermatology

P1476

Prognostic factors, prognostic ...... ry syndrome: where are we now?

@en

P2093

G S Wood

http://www.w3.org/2001/XMLSchema#string

H M Prince

http://www.w3.org/2001/XMLSchema#string

J J Scarisbrick

http://www.w3.org/2001/XMLSchema#string

M H Vermeer

http://www.w3.org/2001/XMLSchema#string

P Quaglino

http://www.w3.org/2001/XMLSchema#string

S J Whittaker

http://www.w3.org/2001/XMLSchema#string

Y H Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Lessons learned from gene expression profiling of cutaneous T-cell lymphoma

The blockade of immune checkpoints in cancer immunotherapy

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Prognostic factor analysis in mycosis fungoides/Sézary syndrome.

Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma

Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis.

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides.

Changing incidence trends of cutaneous T-cell lymphoma.

P304

1226-1236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJD.12909

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260914215

http://www.w3.org/2001/XMLSchema#string

P698

24641480

http://www.w3.org/2001/XMLSchema#string